Menopause Testosterone Therapy: Evidence-Based Position

A Targeted Therapy for a Specific Symptom, Not a Panacea

Menopause and perimenopause can bring a cluster of symptoms, and the search for relief often leads to discussions about hormone therapy. Among the most prominent and contentious topics is the use of androgens, like testosterone, and the marketing of “bioidentical” hormone preparations. A new position statement from the Latin American Association of Gynecological Endocrinology clarifies what the existing high-quality evidence actually supports—and, crucially, what it does not. This evidence-based guidance separates clear clinical indications from practices lacking scientific support.

Limited Evidence Confirms Testosterone for a Single, Well-Defined Condition

Led by Dr. Silvina Pilnik and a multinational panel of experts, the ALEG statement offers a Grade A (high) recommendation based on consistent data: testosterone therapy should be reserved for postmenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). This diagnosis requires a formal biopsychosocial evaluation, a step essential for distinguishing hormonally-influenced low desire from issues related to relationship dynamics, mental health, medications, or other medical conditions. The panel stresses that routine measurement of serum testosterone or other androgens is not recommended for diagnosis, as there is no reliable “threshold” level that predicts symptom relief.

Mechanistically, testosterone influences libido by acting on receptors in the brain’s limbic system, modulating neurotransmitters like dopamine that drive sexual motivation. In menopause, declining ovarian production of precursor hormones leads to lower testosterone availability. However, the panel emphasizes that a low level alone is not an automatic ticket to therapy. They advise checking a baseline level before treatment primarily for safety—to exclude women who already have elevated concentrations that could be exacerbated by treatment, potentially increasing risks like acne or unwanted hair growth.

“Bioidentical” and Off-Label Preparations Carry Specific Risks

A central concern addressed by the Latin American experts is the lack of approved testosterone products for women in their region, a scenario that leads to off-label use of products formulated for men or non-standardized compounded preparations. The statement makes clear distinctions:

Transdermal formulations (gels, patches) are preferred because they allow for controlled dosing that can maintain levels within the premenopausal physiological range, which is the stated goal of therapy.

Subcutaneous pellets and compounded “bioidentical” testosterone receive a Grade C (low) recommendation against their use. The reason is twofold: these delivery methods often produce supraphysiological (above normal) hormone levels that are sustained for months, and there is insufficient high-quality evidence to support their safety and efficacy profile. The term “bioidentical” refers to hormones chemically identical to those the body produces, but this does not automatically make them safer or better when delivered in unpredictable doses, as is common with custom-compounded products.

The statement also explicitly advises against the systemic use of oral dehydroepiandrosterone (DHEA) for sexual symptoms, giving it a Grade A (high) recommendation against. DHEA is a precursor hormone converted to testosterone and estrogen. The panel concludes current evidence does not support its effectiveness for systemic symptoms like low libido, though vaginal DHEA is a recognized treatment for the genitourinary syndrome of menopause, targeting local vaginal dryness and discomfort.

Navigating Treatment: Practical Steps for Patients and Clinicians

This position statement translates into several practical applications for women considering androgen therapy. First, a detailed conversation with a healthcare provider is essential to determine if symptoms align with HSDD or other conditions. For instance, bioidentical testosterone for menopause often comes up in these discussions, and the ALEG guidelines provide critical context for its risks.

Second, if testosterone therapy is pursued for confirmed HSDD, patients must be informed that its use is off-label. Treatment should start with a transdermal product at the lowest effective dose. Monitoring should occur within 3-6 weeks to assess symptom response and check for side effects, with the aim of keeping testosterone levels in the premenopausal range.

Finally, the guidance underscores that androgen therapy is not a first-line or general solution for menopause symptoms like hot flashes, sleep problems, or mood changes. For these, established treatments like estrogen therapy, certain antidepressants, or non-hormonal approaches such as cognitive behavioral therapy for sleep and hot flushes may be more appropriate. Women experiencing abnormal uterine bleeding in perimenopause should also have that addressed before considering androgen therapy.

Conclusion

The ALEG position statement offers a clear, evidence-based path through a complex treatment landscape. It confirms a narrow but important role for testosterone in postmenopausal HSDD while cautioning against unproven and potentially risky practices like systemic DHEA or non-standardized compounded testosterone. Informed, shared decision-making between patients and providers, grounded in the latest science, is the cornerstone of safe and effective hormonal health management during menopause.

Sources:
https://pubmed.ncbi.nlm.nih.gov/40919649/
https://pubmed.ncbi.nlm.nih.gov/40109076/
https://pubmed.ncbi.nlm.nih.gov/38980733/